Sumary of Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern:
- A nationwide case-control study conducted in France has assessed the efficacy of mRNA-based coronavirus disease 2019 (COVID-19) vaccines against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, including B.
- 1.351, and P1. In real-life pandemic situations, the two-dose regimen of mRNA vaccines has shown equivalent protective efficacy against the original virus and B.
- The study has recently been published in the journal The Lancet Regional Health – Europe.
- Background Within one year of the emergence of the COVID-19 pandemic, several potent vaccines were been developed against the original Wuhan strain of SARS-CoV-2. However, with the progression of the pandemic, multiple viral variants with significantly high infectivity have emerged and soon become predominant in many countries worldwide.
- In real-world pandemic situations, most COVID-19 vaccines have shown equivalent efficacy against the original SARS-CoV-2 and the B.
- In the current study, the scientists have assessed the efficacy of a two-dose regimen of mRNA-based COVID-19 vaccines against predominantly circulating variants in France, which are mostly original SARS-CoV-2 and variants B.
- 1.351, and P1. Study design Related StoriesThis nationwide case-control study was conducted on 7,288 adults infected with the original SARS-CoV-2 virus, 31,313 with the B.
- All participants were asked to complete an online survey questionnaire designed to collect information about sociodemographic characteristics, preexisting health conditions, recent SARS-CoV-2 testing results, recent activity-related viral exposures, and vaccination details.